Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
According to previous studies, viral pneumonia can develop into pulmonary fibrosis, which can
affect patients'lung function and even life health.This study aims to observe the efficacy
and safety of Fuzheng Huayu Tablets in the treatment of pulmonary fibrosis after COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
ShuGuang Hospital
Collaborators:
Hubei Hospital of Traditional Chinese Medicine Jingmen No.1 People's Hospital Jingmen No.1 People’s Hospital Tongji Hospital Wenzhou Central Hospital Wuhan No.1 Hospital Wuhan Third Hospital Wuhan Union Hospital, China